Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic growth. The authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein IGFBP-3 in community-dwelling men to determine whether this laboratory finding is manifest at the population level. Participants (n = 471) were Olmsted County, Minnesota, Caucasian males aged 40-79 years in 1990. Urologic measures were assessed from the International Prostate Symptom Score, peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA), and serum IGF-I and IGFBP-3 levels were measured. After adjustment for age, the relative odds (odds ratios) of an abnormal urologic measure in men with high versus low serum IGF-I levels were 0.98 (95% confidence interval (CI): 0.66, 1.45) for a symptom score of >7, 1.14 (95% CI: 0.72, 1.80) for a peak urinary flow rate of <12 ml/second, 1.11 (95% CI: 0.72, 1.72) for a prostate volume of >30 ml, and 0.71 (95% CI: 0.46, 1.09) for a PSA level of >1.4 ng/ml. A low IGFBP-3 level was associated with an enlarged prostate (odds ratio = 1.72, 95% CI: 1.05, 2.82), after simultaneous adjustment for IGF-I and age, but not with other urologic measures. These data do not provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.
IGF-I, IGFBP-3, and Urologic Measures of Benign Prostatic Hyperplasia 785
Am J Epidemiol 2003;157:784-791 bias (15, 16) ; high IGF-I levels may increase benign prostatic growth, increase care-seeking for urologic symptoms, and thereby increase the likelihood that subclinical prostate cancer will be detected.
IGFBP-3, the most abundant of the IGFBPs, has also been associated with prostatic growth. Seventy-five percent of IGF-I is bound to IGFBP-3, 20-25 percent is bound to the other binding proteins (IGFBP 1, 2, 4, and 5), and less than 1 percent is carried in the unbound state in the circulation (17) . Therefore, relative concentrations of IGFBP-3 may influence serum and, possibly, prostatic tissue levels of IGF-I. Importantly, although the IGFBP-3-IGF-I complex is a high molecular weight protein that cannot diffuse into tissues, complexes of IGF-I and other IGFBPs have a lower molecular weight and can traverse the capillary membrane into tissues (17, 18) . Consequently, a decrease in IGFBP-3 levels may lead to greater binding of IGF-I to other IGFBPs, increased diffusion into tissues, and an increase in tissue IGF-I levels, resulting in increased prostatic growth. High levels of IGFBP-3 have been associated with a decreased risk of prostate cancer (8) , but other studies have found no significant association between IGFBP-3 and prostate cancer risk (9, 12, 19) . Higher levels of IGFBP-3 have also been associated with greater prostatic volume in AfricanAmerican men (20) .
While these previous studies provide some support for a potential role of IGF-I and IGFBP-3 in the development of benign prostatic hyperplasia, to our knowledge this potential association has not been fully evaluated in communitydwelling men. Since prostatic tissue IGF-I levels are influenced by serum IGF-I and IGFBP-3 levels (21), we hypothesized that high serum IGF-I and/or low IGFBP-3 levels should be associated with a greater likelihood of benign prostatic hyperplasia. This study provided the opportunity to test this hypothesis by using information on serum IGF-I and IGFBP-3 levels and surrogate measures of benign prostatic hyperplasia from a cohort of community-dwelling men.
MATERIALS AND METHODS

Study subjects
Subjects were participants in a longitudinal study of lower urinary tract symptoms and benign prostatic hyperplasia. The study selection details have been described previously (22, 23) . A sampling frame of Caucasian males living in Olmsted County, Minnesota, and aged 40-79 years on January 1, 1990, was created by using electronic databases (24, 25) . From this sampling frame, a random sample of men was selected, and their medical records were examined for exclusion criteria that included a history of prostatectomy, prostate cancer, or other known medical conditions, other than benign prostatic hyperplasia, that could impair normal voiding function. Of the 3,874 men eligible, 2,115 agreed to participate (55 percent participation rate). A 25 percent (n = 537) random subsample (clinic cohort) was selected from the 2,115 men for a more detailed clinical investigation, and 471 men participated (88 percent participation rate) (26) .
Follow-up was performed biennially by using the same protocol as at baseline: questionnaires, determination of peak urinary flow rates (Qmax), and clinical measurements including transrectal ultrasound to determine prostate volume as well as a blood draw for serum measurements. For the first and second evaluations, men who refused to participate, had died, or were lost to follow-up were replaced by similarly aged men from the community (27) by using the same selection criteria as at baseline. The present study used serum measurements and assessments from the 1996 followup round to assess the cross-sectional relation between total serum IGF-I and IGFBP-3 and the urologic measures.
Clinic cohort measurements
Questionnaire and uroflow evaluation. At baseline, study subjects completed a previously validated questionnaire that included items similar to the International Prostate Symptom Score, and a composite score was estimated for each subject (28) . Qmax was also measured in private by using a standard uroflowmeter, with subjects in a standing position.
Clinical evaluation. Each subject underwent a blood draw and determination of serum prostate-specific antigen (PSA) prior to any prostatic manipulation, including a digital rectal examination. A transrectal ultrasound was performed by using a 7.5-MHz, biplanar endorectal transducer. The anterior posterior, transverse, and superior inferior dimensions were measured and prostate volume was calculated by using the formula for a prolate ellipsoid: volume = 0.52 (transverse × anterior posterior × superior inferior) (29) . Men found to have prostate cancer on the basis of this evaluation with biopsy confirmation were excluded from our analyses.
Laboratory measurements. Total serum IGF-I and IGFBP-3 levels were measured by using immunometric assay kits (Diagnostic System Laboratories, Inc., Webster, Texas). The interassay coefficients of variation were 6.9 percent at 5.8 ng/ml and 14.4 percent at 20.9 ng/ml for IGFBP-3 and 9 percent at 64 ng/ml and 6.2 percent at 157 ng/ml for IGF-I. Serum PSA levels were measured by using the Hybritech Tandem R assay (Hybritech Inc., San Diego, California), a solid, phase-two-site immunoradiometric assay. The coefficients of variation for measuring serum PSA in the Mayo Clinic laboratory (Rochester, Minnesota) are 6.22 percent at 2.88 ng/ml and 6.82 percent at 41.6 ng/ ml.
Statistical analysis
Descriptive statistics were estimated for the 1996 measurements of serum IGF-I and IGFBP-3 (exposure variables) and for urologic measures of benign prostatic hyperplasia determined from the 1996 evaluation: International Prostate Symptom Score, Qmax, prostate volume, and serum PSA level (a surrogate measure of prostate size). Urologic measures were dichotomized on the basis of standard cutpoints (26, 28, 30) as a symptom score of ≤7 and >7 (moderate or severe symptoms), Qmax of ≥12 and <12 ml/ second (low Qmax), and prostate volume of ≤30 ml and >30 ml (enlarged prostate); serum PSA was dichotomized at the median (≤1.4 and >1.4 ng/ml). Cutpoints for IGF-I and IGFBP-3 based on medians and tertiles were used to divide the study cohort into two and three groups, respectively. The associations between urologic measures and exposure variables were assessed by using Wilcoxon rank sum and Kruskall-Wallis tests of association, and odds ratios and 95 percent confidence intervals were estimated from logistic regression models. A test for trend across tertiles was examined by using logistic regression models. Since age could be a correlate of the serum markers, in which case adjusting for age could be inappropriate, the results with and without adjustment for age are presented in this paper. Analyses stratified by 10-year age groups were performed to assess potential effect modification by age, and homogeneity of the odds ratio was assessed by using the Breslow-Day test.
RESULTS
The distributions of and correlations between IGF-I and IGFBP-3 levels and urologic measures are presented in table 1. Among the 471 study subjects, mean values were 59.2 years for age, 8.0 for International Prostate Symptom Score, 19.4 ml/second for Qmax, 29.9 ml for prostate volume, and 1.4 ng/ml for serum PSA level. Significant negative correlations were found between serum IGFBP-3 level and prostate volume, serum PSA, International Prostate Symptom Score, and age, and a positive correlation was found between serum IGFBP-3 level and Qmax. There were also significant negative correlations between IGF-I and serum PSA levels and between IGF-I level and age, and a strong positive correlation was found between IGF-I and IGFBP-3 levels (r s = 0.61, p = 0.001). After adjustment for age, the correlations between IGF-I, IGFBP-3, and urologic measures were not statistically significant.
Benign prostatic hyperplasia surrogate measures and IGF-I
Mean serum IGF-I levels were significantly higher in men whose serum PSA was ≤1.4 ng/ml compared with >1. (table 3) . With adjustment for the effects of age, the association between serum IGF-I and serum PSA levels was no longer statistically significant (table 3) . No trends were observed with IGF-I level.
Benign prostatic hyperplasia surrogate measures and IGFBP-3
Mean serum IGFBP-3 levels were significantly lower in men with greater symptom severity (International Prostate Symptom Score >7), depressed Qmax (<12 ml/second), an enlarged prostate (>30 ml), or an elevated serum PSA level (>1.4 ng/ml) compared with men with a symptom score of ≤7, Qmax of >12 ml/second, prostate volume of <30 ml, or PSA level of <1.4 ng/ml (table 2). In addition, mean serum IGFBP-3 levels were lower across successively older groups of men. These results were corroborated in logistic regression analyses. In bivariate analyses, a low IGFBP-3 (<median) level was associated with an elevated relative odds of an enlarged prostate (OR = 1.90, 95 percent CI: 1.27, 2.89) and a PSA level of >1.4 ng/ml (OR = 1.71, 95 percent CI: 1.14, 2.55) ( In multivariable models with simultaneous adjustment for serum IGFBP-3 and IGF-I, serum IGFBP-3 was significantly associated with prostate volume, but no other significant associations were found between serum IGF-I or IGFBP-3 levels and the other urologic measures. A low serum IGFBP-3 level was associated with an increased like- 
DISCUSSION
In this study, we evaluated the cross-sectional association between serum levels of IGF-I and IGFBP-3 and surrogate markers of benign prostatic hyperplasia in a random sample of Caucasian, community-dwelling men. IGF-I has powerful mitogenic and antiapoptotic effects in many tissues (6, 7) . These effects may be modulated by concentrations of IGFBP-3 in the peripheral circulation (21, 31) , with increases in serum IGFBP-3 levels attenuating the mitogenic and antiapoptotic effects of IGF-I in tissues. Thus, we would expect to find a direct association between serum levels of IGF-I and our surrogate measures of benign prostatic hyperplasia and an inverse relation between serum levels of IGFBP-3 and these measures of benign prostatic hyperplasia.
For IGF-I, our cross-sectional data did not support these expected relations. Without adjustment for age, there was the suggestion of nonsignificant inverse associations between high IGF-I levels and urologic measures, a direction opposite to what was hypothesized. After adjustment for age, the point estimates for the associations between serum IGF-I and International Prostate Symptom Score, Qmax, and prostate volume approached 1, but the estimate for the association with serum PSA remained below 1. These nonsignificant findings could reflect the limits of cross-sectional data that provide a snapshot of inherently dynamic processes, could indicate that serum concentrations do not reflect intracellular levels where the biologic activity takes place (18, 21) , or could indicate that there is no association.
By contrast, the cross-sectional associations between serum IGFBP-3 levels and urologic measures in this study were in the hypothesized direction, although they were of modest magnitude. Moreover, the unadjusted dose-response relation with prostate volume provided further credence to this relation. Although this finding is consistent with the hypothesis that more IGF-I may be bioavailable when IGFBP-3 levels are low, when IGFBP-3 was taken into account as either a confounder or an effect modifier, still no significant association was found between serum IGF-I levels and urologic measures. Adjustment for age did not dramatically alter these relations, but the statistical significance of the association between serum IGFBP-3 and serum PSA levels was lost. This finding suggests that the observed association may be a consequence of the confounding effects of age. In fact, when the analyses were stratified by age, we found no significant relation between serum IGFBP-3 levels and measures of benign prostatic hyperplasia within any of the age-specific strata (data not shown).
Other investigators have examined the associations between serum IGF-I or IGFBP-3 level and benign prostatic hyperplasia (11, 32, 33) or prostate size (12, 20) . In general, the study findings were similar to ours in that the investigators observed no significant associations between serum IGF-I or serum IGFBP-3 level and benign prostatic hyperplasia (11, 12, 32) . However, Chokkalingam et al. (33) observed a significant dose-response association between increasing IGFBP-3 level and prostate volume and a significant trend in risk of benign prostatic hyperplasia with increasing serum IGF-I level after adjustment for age. In our study, the dose-response association between IGFBP-3 and prostate volume was no longer evident after adjustment for age. Sarma et al. (20) reported an inverse correlation between IGF-I and prostate volume and a positive ageadjusted correlation between serum IGFBP-3 levels and prostate volume. The latter finding was in contrast to ours. The reported serum IGFBP-3 levels were similar to levels in Olmsted County men, but serum IGF-I levels were much lower; the reason is not apparent.
In a study of Finnish men that examined the association of prostate cancer with IGF-I and IGFBP-3, men with benign prostatic hyperplasia were used as controls (16) . Reported serum IGF-I and IGFBP-3 levels and mean prostate volume for men with benign prostatic hyperplasia were higher than for men in our study and may suggest an association with benign prostatic hyperplasia (15) , but no associations with urologic measures of benign prostatic hyperplasia were examined. The differences in findings across studies may relate to 1) variations in the definition and disease spectrum of benign prostatic hyperplasia: histologic benign prostatic hyperplasia (32, 33) , prostate size (12, 20) , or a more broadspectrum definition based on surrogate measures, as in our study; 2) differences in assays for measuring serum IGF-I and IGFBP-3 levels (15, 34); or 3) racial differences in IGF-I and IGFBP-3 levels (35, 36) It is difficult to discern the meaning of our findings because of the complex interrelations between prostatic tissue and serum levels of IGF-I and IGFBP-3 and with intraprostatic androgens (5, 37) . In a dynamic, in vivo system, it is difficult to evaluate the independent effects of each protein on prostatic growth. Through homeostatic mechanisms, changes in levels of one metabolite could result in compensatory responses. With cross-sectional data, the ability to assess temporal relations is lost.
Assessment of benign prostatic hyperplasia also complicates our ability to understand the associations with these proteins. Benign prostatic hyperplasia is a histologic diagnosis, but since it is not practical to perform a biopsy in order to make the diagnosis, it is necessary to rely on surrogate measures to define the condition. However, no single surrogate measure is a perfect marker for benign prostatic hyperplasia, and correlations among the surrogate measures are only modest (38) . Each measure has a component related to benign prostatic hyperplasia and one due to other causes. Therefore, it is important to evaluate the association between exposure variables and more than one surrogate measure of benign prostatic hyperplasia. The suggestion of an associa- tion between serum IGFBP-3 levels and prostate volume, but not with serum PSA level (an indirect measure of epithelial volume) (39) or the other measures, may indicate that IGFBP-3 levels are associated with stromal proliferation.
Other potential limitations should be noted when interpreting our results. With each of the urologic measures, measurement error (random variability) could have reduced our ability to detect a correlation or an association. Although the participation rate of 55 percent for the entire cohort suggests a potential for bias, it seems unlikely that participants would differ from nonparticipants in outcomes conditional on exposure (IGF-I or IGFBP-3). A review of the medical records of participants and nonparticipants, after approval by the Mayo Institutional Review Board, indicated a slightly older age and a higher prevalence of urologic diagnoses among participants (40) that did not appear to bias long-term outcomes (30) . Finally, our findings are generalizable primarily to Caucasian men, and extrapolation of these findings to men not represented in the study should be performed with caution.
In summary, our data failed to demonstrate significant associations between serum levels of IGF-I and surrogate measures of benign prostatic hyperplasia. However, they suggest that low serum levels of IGFBP-3 may be associated with increased prostate size, although this possibility may just reflect confounding by age.
